We are live on ! Find out more
BBIO icon

BridgeBio Pharma
BBIO

88 hedge funds and large institutions have $3.67B invested in BridgeBio Pharma in 2019 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 31 increasing their positions, 16 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

190% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 10

94% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 16

65% more capital invested

Capital invested by funds: $2.22B → $3.67B (+$1.45B)

40% more funds holding in top 10

Funds holding in top 10: 5 → 7 (+2)

17% more funds holding

Funds holding: 75 → 88 (+13)

1.71% less ownership

Funds ownership: 88.47% → 86.77% (-1.7%)

Holders
88
Holders Change
+13
Holders Change %
+17.33%
% of All Funds
1.73%
Holding in Top 10
7
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+40%
% of All Funds
0.14%
New
29
Increased
31
Reduced
16
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$74.5M
2
BlackRock
BlackRock
New York
+$32.8M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$15.2M
4
State Street
State Street
Massachusetts
+$12.7M
5
N
Nuveen
North Carolina
+$12.4M

Top Sellers

Rank Fund Capital Flow
1
Victory Capital Management
Victory Capital Management
Texas
-$19.7M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$12.3M
3
SM
SCGE Management
California
-$8.93M
4
DM
Deerfield Management
New York
-$6.23M
5
CAM
Cormorant Asset Management
Massachusetts
-$2.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
KKRC
1
Kohlberg Kravis Roberts & Co
New York
$1.29B – – –
Viking Global Investors
2
Viking Global Investors
Connecticut
$933M – – –
AIG
3
American International Group
New York
$236M -$58.7K -2,119 -0%
HA
4
HHLR Advisors
Cayman Islands
$154M – – –
PA
5
Perceptive Advisors
New York
$142M – – –
ACM
6
Aisling Capital Management
New York
$134M – – –
Janus Henderson Group
7
Janus Henderson Group
United Kingdom
$110M +$74.5M +2,688,910 +595%
BlackRock
8
BlackRock
New York
$93.2M +$32.8M +1,184,951 +80%
SUT
9
SC US (TTGP)
California
$89.2M – – –
CAM
10
Cormorant Asset Management
Massachusetts
$88.1M -$2.9M -104,701 -4%
Fidelity Investments
11
Fidelity Investments
Massachusetts
$76.9M -$12.3M -444,438 -17%
Vanguard Group
12
Vanguard Group
Pennsylvania
$75M +$15.2M +548,046 +34%
Lord, Abbett & Co
13
Lord, Abbett & Co
New Jersey
$33.6M +$4.39M +158,380 +20%
State Street
14
State Street
Massachusetts
$28.3M +$12.7M +456,605 +130%
JP Morgan Chase
15
JP Morgan Chase
New York
$20.8M +$104K +3,755 +0.6%
N
16
Nuveen
North Carolina
$18.8M +$12.4M +448,791 +514%
TCM
17
TimesSquare Capital Management
New York
$17.4M -$1.19M -42,780 -8%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$12.2M +$331K +11,930 +4%
Massachusetts Financial Services
19
Massachusetts Financial Services
Massachusetts
$11M +$2.66K +96 +0%
Northern Trust
20
Northern Trust
Illinois
$10.8M +$250K +9,033 +3%
Franklin Resources
21
Franklin Resources
California
$9.93M -$1.85M -66,700 -19%
Goldman Sachs
22
Goldman Sachs
New York
$7.92M +$1.53M +55,177 +32%
AG
23
Artal Group
Luxembourg
$7.01M – – –
Charles Schwab
24
Charles Schwab
California
$4.66M +$188K +6,788 +5%
Norges Bank
25
Norges Bank
Norway
$4.27M -$781K -28,183 -19%
1
2 3 4

BBIO Hedge Fund Activity: Q4 2019 in Review

88 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Pharma (BBIO) for Q4 2019, worth a combined $3.67B — up 65% from $2.22B a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new BBIO positions and 10 closed out — a net gain of 19 holders — while 31 added to existing stakes and 16 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $74.5M. The largest seller was Victory Capital Management, cutting an estimated $19.7M.

  • 88 institutional investors held BridgeBio Pharma (BBIO) as of Q4 2019, up from 75 in Q3 2019.
  • Funds reported $3.67B of BridgeBio Pharma stock for Q4 2019, up 65% quarter-over-quarter.
  • 29 funds opened new BridgeBio Pharma positions in Q4 2019 and 10 closed out, a net change of +19 holders.
  • The largest BridgeBio Pharma buyer in Q4 2019 was Janus Henderson Group, an estimated $74.5M added.
  • The largest BridgeBio Pharma seller in Q4 2019 was Victory Capital Management, an estimated $19.7M sold.

Based on aggregated 13F filings for Q4 2019.